Successive remodeling of IgG glycans using a solid-phase enzymatic platform.
Journal
Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179
Informations de publication
Date de publication:
07 04 2022
07 04 2022
Historique:
received:
27
09
2021
accepted:
11
03
2022
entrez:
8
4
2022
pubmed:
9
4
2022
medline:
12
4
2022
Statut:
epublish
Résumé
The success of glycoprotein-based drugs in various disease treatments has become widespread. Frequently, therapeutic glycoproteins exhibit a heterogeneous array of glycans that are intended to mimic human glycopatterns. While immunogenic responses to biologic drugs are uncommon, enabling exquisite control of glycosylation with minimized microheterogeneity would improve their safety, efficacy and bioavailability. Therefore, close attention has been drawn to the development of glycoengineering strategies to control the glycan structures. With the accumulation of knowledge about the glycan biosynthesis enzymes, enzymatic glycan remodeling provides a potential strategy to construct highly ordered glycans with improved efficiency and biocompatibility. In this study, we quantitatively evaluate more than 30 enzymes for glycoengineering immobilized immunoglobulin G, an impactful glycoprotein class in the pharmaceutical field. We demonstrate successive glycan remodeling in a solid-phase platform, which enabled IgG glycan harmonization into a series of complex-type N-glycoforms with high yield and efficiency while retaining native IgG binding affinity.
Identifiants
pubmed: 35393560
doi: 10.1038/s42003-022-03257-4
pii: 10.1038/s42003-022-03257-4
pmc: PMC8990068
doi:
Substances chimiques
Glycoproteins
0
Immunoglobulin G
0
Polysaccharides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
328Informations de copyright
© 2022. The Author(s).
Références
Spiro, R. G. Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. Glycobiology 12, 43–56 (2002).
doi: 10.1093/glycob/12.4.43R
Apweiler, R., Hermjakob, H. & Sharon, N. On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. Biochim Biophys. Acta 1473, 4–8 (1999).
pubmed: 10580125
doi: 10.1016/S0304-4165(99)00165-8
Reily, C., Stewart, T. J., Renfrow, M. B. & Novak, J. Glycosylation in health and disease. Nat. Rev. Nephrol. 15, 346–366 (2019).
pubmed: 30858582
pmcid: 6590709
doi: 10.1038/s41581-019-0129-4
Maverakis, E. et al. Glycans in the immune system and The Altered Glycan Theory of Autoimmunity: a critical review. J. Autoimmun. 57, 1–13 (2015).
pubmed: 25578468
doi: 10.1016/j.jaut.2014.12.002
Reiding, K. R. et al. Serum Protein N-Glycosylation Changes with Rheumatoid Arthritis Disease Activity during and after Pregnancy. Front. Med. (Lausanne) 4, 241 (2017).
Mimura, Y. et al. Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy. Protein Cell 9, 47–62 (2018).
pubmed: 28597152
doi: 10.1007/s13238-017-0433-3
Goetze, A. M. et al. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology 21, 949–959 (2011).
pubmed: 21421994
doi: 10.1093/glycob/cwr027
Chiang, A. W. et al. Modulating carbohydrate-protein interactions through glycoengineering of monoclonal antibodies to impact cancer physiology. Curr. Opin. Struct. Biol. 40, 104–111 (2016).
pubmed: 27639240
pmcid: 5161599
doi: 10.1016/j.sbi.2016.08.008
Wong, C.-H. Protein Glycosylation: New Challenges and Opportunities. J. Org. Chem. 70, 4219–4225 (2005).
pubmed: 15903293
doi: 10.1021/jo050278f
Ma, B. et al. Protein Glycoengineering: An Approach for Improving Protein Properties. Front. Chem. 8, 622 (2020).
Nagasaki, M. et al. Chemical Synthesis of a Complex-Type N-Glycan Containing a Core Fucose. J. Org. Chem. 81, 10600–10616 (2016).
pubmed: 27775350
doi: 10.1021/acs.joc.6b02106
Wang, Z. et al. A general strategy for the chemoenzymatic synthesis of asymmetrically branched N-glycans. Science 341, 379–383 (2013).
pubmed: 23888036
doi: 10.1126/science.1236231
Li, T. et al. An automated platform for the enzyme-mediated assembly of complex oligosaccharides. Nat. Chem. 11, 229–236 (2019).
pubmed: 30792508
pmcid: 6399472
doi: 10.1038/s41557-019-0219-8
Umekawa, M. et al. Efficient glycosynthase mutant derived from Mucor hiemalis endo-beta-N-acetylglucosaminidase capable of transferring oligosaccharide from both sugar oxazoline and natural N-glycan. J. Biol. Chem. 285, 511–521 (2010).
pubmed: 19880511
doi: 10.1074/jbc.M109.059832
Lin, C. W. et al. A common glycan structure on immunoglobulin G for enhancement of effector functions. Proc. Natl Acad. Sci. USA 112, 10611–10616 (2015).
pubmed: 26253764
pmcid: 4553773
doi: 10.1073/pnas.1513456112
Yang, Z. et al. Engineered CHO cells for production of diverse, homogeneous glycoproteins. Nat. Biotechnol. 33, 842–844 (2015).
pubmed: 26192319
doi: 10.1038/nbt.3280
Liu, C. P. et al. Glycoengineering of antibody (Herceptin) through yeast expression and in vitro enzymatic glycosylation. Proc. Natl Acad. Sci. USA 115, 720–725 (2018).
pubmed: 29311294
pmcid: 5789950
doi: 10.1073/pnas.1718172115
Higel, F., Seidl, A., Sörgel, F. & Friess, W. N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins. Eur. J. Pharmaceutics Biopharmaceutics 100, 94–100 (2016).
doi: 10.1016/j.ejpb.2016.01.005
Lairson, L. L., Henrissat, B., Davies, G. J. & Withers, S. G. Glycosyltransferases: Structures, Functions, and Mechanisms. Annu. Rev. Biochem. 77, 521–555 (2008).
pubmed: 18518825
doi: 10.1146/annurev.biochem.76.061005.092322
Sjögren, J., Lood, R. & Nägeli, A. On enzymatic remodeling of IgG glycosylation; unique tools with broad applications. Glycobiology 30, 254–267 (2019).
pmcid: 7109354
doi: 10.1093/glycob/cwz085
Hamilton, B. S. et al. A library of chemically defined human N-glycans synthesized from microbial oligosaccharide precursors. Sci. Rep. 7, 15907 (2017).
pubmed: 29162910
pmcid: 5698433
doi: 10.1038/s41598-017-15891-8
Liu, L. et al. Streamlining the chemoenzymatic synthesis of complex N-glycans by a stop and go strategy. Nat. Chem. 11, 161–169 (2019).
pubmed: 30532014
doi: 10.1038/s41557-018-0188-3
Thomann, M. et al. In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity. PLoS One 10, e0134949 (2015).
Tang, F. et al. One-pot N-glycosylation remodeling of IgG with non-natural sialylglycopeptides enables glycosite-specific and dual-payload antibody–drug conjugates. Org. Biomolecular Chem. 14, 9501–9518 (2016).
doi: 10.1039/C6OB01751G
Huang, W., Giddens, J., Fan, S.-Q., Toonstra, C. & Wang, L.-X. Chemoenzymatic Glycoengineering of Intact IgG Antibodies for Gain of Functions. J. Am. Chem. Soc. 134, 12308–12318 (2012).
pubmed: 22747414
pmcid: 3427744
doi: 10.1021/ja3051266
Li, T., Tong, X., Yang, Q., Giddens, J. P. & Wang, L.-X. Glycosynthase Mutants of Endoglycosidase S2 Show Potent Transglycosylation Activity and Remarkably Relaxed Substrate Specificity for Antibody Glycosylation Remodeling. J. Biol. Chem. 291, 16508–16518 (2016).
pubmed: 27288408
pmcid: 4974367
doi: 10.1074/jbc.M116.738765
Giddens, J. P., Lomino, J. V., DiLillo, D. J., Ravetch, J. V. & Wang, L. X. Site-selective chemoenzymatic glycoengineering of Fab and Fc glycans of a therapeutic antibody. Proc. Natl Acad. Sci. USA 115, 12023–12027 (2018).
pubmed: 30397147
pmcid: 6255169
doi: 10.1073/pnas.1812833115
Coin, I., Beyermann, M. & Bienert, M. Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences. Nat. Protoc. 2, 3247–3256 (2007).
pubmed: 18079725
doi: 10.1038/nprot.2007.454
Lu, R.-M. et al. Development of therapeutic antibodies for the treatment of diseases. J. Biomed. Sci. 27, 1 (2020).
pubmed: 31894001
pmcid: 6939334
doi: 10.1186/s12929-019-0592-z
Pucić, M. et al. High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations. Mol. Cell Proteomics 10, M111.010090 (2011).
Li, T. et al. Modulating IgG effector function by Fc glycan engineering. Proc. Natl Acad. Sci. 114, 3485–3490 (2017).
pubmed: 28289219
pmcid: 5380036
doi: 10.1073/pnas.1702173114
Gudelj, I., Lauc, G. & Pezer, M. Immunoglobulin G glycosylation in aging and diseases. Cell. Immunol. 333, 65–79 (2018).
pubmed: 30107893
doi: 10.1016/j.cellimm.2018.07.009
Stockert, R. J. The asialoglycoprotein receptor: relationships between structure, function, and expression. Physiol. Rev. 75, 591–609 (1995).
pubmed: 7624395
doi: 10.1152/physrev.1995.75.3.591
Higel, F. et al. N-glycans of complex glycosylated biopharmaceuticals and their impact on protein clearance. Eur. J. Pharmaceutics Biopharmaceutics 139, 123–131 (2019).
doi: 10.1016/j.ejpb.2019.03.018
Stanley, P., Taniguchi, N. & Aebi, M. Essentials of Glycobiology. Third edn, 99–111 (Cold Spring Harbor, 2015).
Mizushima, T. et al. Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes Cells 16, 1071–1080 (2011).
pubmed: 22023369
pmcid: 3258418
doi: 10.1111/j.1365-2443.2011.01552.x
Shields, R. L. et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277, 26733–26740 (2002).
pubmed: 11986321
doi: 10.1074/jbc.M202069200
Breton, C., Šnajdrová, L., Jeanneau, C., Koča, J. & Imberty, A. Structures and mechanisms of glycosyltransferases. Glycobiology 16, 29–37 (2005).
doi: 10.1093/glycob/cwj016
Harbison, A. M., Brosnan, L. P., Fenlon, K. & Fadda, E. Sequence-to-structure dependence of isolated IgG Fc complex biantennary N-glycans: a molecular dynamics study. Glycobiology 29, 94–103 (2018).
doi: 10.1093/glycob/cwy097
Barb, A. W., Brady, E. K. & Prestegard, J. H. Branch-specific sialylation of IgG-Fc glycans by ST6Gal-I. Biochemistry 48, 9705–9707 (2009).
pubmed: 19772356
doi: 10.1021/bi901430h
Amado, M., Almeida, R., Schwientek, T. & Clausen, H. Identification and characterization of large galactosyltransferase gene families: galactosyltransferases for all functions. Biochimica et. Biophysica Acta 1473, 35–53 (1999).
pubmed: 10580128
doi: 10.1016/S0304-4165(99)00168-3
Okada, T. et al. Glycoscience: Biology and Medicine. Control of Glycans by Enzyme Competitions. 1163–1171 (Springer Japan, 2015).
Gagarinov, I. A. et al. Chemoenzymatic Approach for the Preparation of Asymmetric Bi-, Tri-, and Tetra-Antennary N-Glycans from a Common Precursor. J. Am. Chem. Soc. 139, 1011–1018 (2017).
pubmed: 28002670
pmcid: 5461401
doi: 10.1021/jacs.6b12080
Yip, B., Chen, S. H., Mulder, H., Höppener, J. W. & Schachter, H. Organization of the human beta-1,2-N-acetylglucosaminyltransferase I gene (MGAT1), which controls complex and hybrid N-glycan synthesis. Biochem J. 321, 465–474 (1997).
pubmed: 9020882
pmcid: 1218092
doi: 10.1042/bj3210465
Narasimhan, S. Control of glycoprotein synthesis. UDP-GlcNAc:glycopeptide beta 4-N-acetylglucosaminyltransferase III, an enzyme in hen oviduct which adds GlcNAc in beta 1-4 linkage to the beta-linked mannose of the trimannosyl core of N-glycosyl oligosaccharides. J. Biol. Chem. 257, 10235–10242 (1982).
pubmed: 6213618
doi: 10.1016/S0021-9258(18)34010-9
Hodoniczky, J., Zheng, Y. Z. & James, D. C. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol. Prog. 21, 1644–1652 (2005).
pubmed: 16321047
doi: 10.1021/bp050228w
Shoreibah, M. et al. Isolation, characterization, and expression of a cDNA encoding N-acetylglucosaminyltransferase V. J. Biol. Chem. 268, 15381–15385 (1993).
pubmed: 8340368
doi: 10.1016/S0021-9258(18)82268-2
Ihara, H., Ikeda, Y. & Taniguchi, N. Reaction mechanism and substrate specificity for nucleotide sugar of mammalian α1,6-fucosyltransferase—a large-scale preparation and characterization of recombinant human FUT8. Glycobiology 16, 333–342 (2005).
pubmed: 16344263
doi: 10.1093/glycob/cwj068
Boruah, B. M. et al. Characterizing human α−1,6-fucosyltransferase (FUT8) substrate specificity and structural similarities with related fucosyltransferases. J. Biol. Chem. 295, 17027–17045 (2020).
pubmed: 33004438
pmcid: 7863877
doi: 10.1074/jbc.RA120.014625
Krapp, S., Mimura, Y., Jefferis, R., Huber, R. & Sondermann, P. Structural Analysis of Human IgG-Fc Glycoforms Reveals a Correlation Between Glycosylation and Structural Integrity. J. Mol. Biol. 325, 979–989 (2003).
pubmed: 12527303
doi: 10.1016/S0022-2836(02)01250-0
Mimura, Y. et al. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. Mol. Immunol. 37, 697–706 (2000).
pubmed: 11275255
doi: 10.1016/S0161-5890(00)00105-X
Huffman, M. A. et al. Design of an in vitro biocatalytic cascade for the manufacture of islatravir. Science 366, 1255–1259 (2019).
pubmed: 31806816
doi: 10.1126/science.aay8484
Moremen, K. W. & Haltiwanger, R. S. Emerging structural insights into glycosyltransferase-mediated synthesis of glycans. Nat. Chem. Biol. 15, 853–864 (2019).
pubmed: 31427814
pmcid: 6820136
doi: 10.1038/s41589-019-0350-2
Taujale, R. et al. Deep evolutionary analysis reveals the design principles of fold A glycosyltransferases. eLife 9, e54532 (2020).
Walsh, G. Biopharmaceutical benchmarks 2010. Nat. Biotechnol. 28, 917–924 (2010).
pubmed: 20829826
doi: 10.1038/nbt0910-917
Liu, S. et al. Comprehensive N-Glycan Profiling of Cetuximab Biosimilar Candidate by NP-HPLC and MALDI-MS. PLoS One 12, e0170013 (2017).
Laukens, B., De Visscher, C. & Callewaert, N. Engineering yeast for producing human glycoproteins: where are we now? Future Microbiol 10, 21–34 (2015).
pubmed: 25598335
doi: 10.2217/fmb.14.104
Krištić, J. et al. Glycans are a novel biomarker of chronological and biological ages. J. Gerontol. A Biol. Sci. Med Sci. 69, 779–789 (2014).
pubmed: 24325898
doi: 10.1093/gerona/glt190
Waterhouse, A. et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 46, 296–303 (2018).
doi: 10.1093/nar/gky427
Youn, S. J. et al. Construction of novel repeat proteins with rigid and predictable structures using a shared helix method. Sci. Rep. 7, 2595 (2017).
pubmed: 28572639
pmcid: 5454011
doi: 10.1038/s41598-017-02803-z
Ultsch, M., Braisted, A., Maun, H. R. & Eigenbrot, C. 3-2-1: Structural insights from stepwise shrinkage of a three-helix Fc-binding domain to a single helix. Protein Eng. Des. Sel. 30, 619–625 (2017).
pubmed: 28475752
pmcid: 5914316
doi: 10.1093/protein/gzx029